查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1615440

神经胶质瘤治疗市场：按神经胶质瘤类型、治疗类型、最终用户、分销管道划分 - 全球预测 2025-2030

Glioma Treatment Market by Type of Glioma (High-grade Gliomas, Low-grade Gliomas), Treatment Type (Chemotherapy, Immunotherapy, Radiation Therapy), End-user, Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

神经胶质瘤治疗市场2023年估值为49.5亿美元，预计到2024年将达52.9亿美元，复合年增长率为7.43%，预计到2030年将达到81.8亿美元。

神经胶质瘤治疗是指旨在治疗神经胶质瘤的综合方法和治疗方法，神经胶质瘤是一种由神经胶质细胞产生的脑肿瘤。这些肿瘤的侵袭性加剧了对神经胶质瘤治疗的需求，需要从手术干预和放射线治疗到尖端免疫疗法和标靶药物的创新解决方案。应用范围涵盖医院、专业癌症治疗中心和个人化居家医疗环境，以满足不同疾病阶段的不同患者的需求。主要的最终用途领域包括专注于开发和提供有效治疗方法的医疗保健提供者和製药公司。市场成长受到多种因素的影响，例如脑肿瘤盛行率的增加、医疗技术的进步以及政府促进癌症研究的措施。此外，正在进行的临床试验和早期诊断意识的提高也为创新提供了重要的机会。公司可以透过投资生物标记发现研究和非侵入性治疗方法的开发来利用这一潜力。然而，市场扩张面临治疗成本上升、监管复杂性以及新兴地区先进治疗方法方法有限等挑战。快速的技术进步正在塑造竞争格​​局，因此企业必须优先考虑研发并建立策略伙伴关係。最有前途的创新领域包括个人化医疗方法、将人工智慧整合到诊断工具中以及扩展远端医疗用于患者管理。市场动态是动态的，其特征是市场竞争和治疗通讯协定的不断演变。成功的企业必须专注于扩大产品平臺、加强与研究机构的合作、开拓开拓的市场，以保持成长并在市场中脱颖而出。

主要市场统计
基准年[2023] 49.5亿美元
预计年份 [2024] 52.9亿美元
预测年份 [2030] 81.8亿美元
复合年增长率（%） 7.43%

市场动态：揭示快速发展的神经胶质瘤治疗市场的关键市场洞察

供需的动态交互作用正在改变神经胶质瘤治疗市场。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助企业了解消费行为及其对製造业的影响。

  • 市场驱动因素
    • 全球神经胶质瘤盛行率不断增加
    • 神经胶质瘤治疗改革和支持计划
  • 市场限制因素
    • 联合治疗高成本
  • 市场机会
    • 精准医疗技术的进步
    • 旨在发现神经胶质瘤新治疗方法的联合研究和开发工作
  • 市场挑战
    • 目前治疗方法的功效有限且副作用大

波特五力：驾驭神经胶质瘤治疗市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解神经胶质瘤治疗市场的外部影响

外部宏观环境因素在塑造神经胶质瘤治疗市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解神经胶质瘤治疗市场的竞争格局

对神经胶质瘤治疗市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵神经胶质瘤治疗市场供应商的绩效评估

FPNV定位矩阵是评估神经胶质瘤治疗市场供应商的关键工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议绘製神经胶质瘤治疗市场的成功之路

对于旨在加强在全球市场的影响力的公司来说，神经胶质瘤治疗市场的策略分析至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：全面分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监管核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 神经胶质瘤盛行率在全球范围内不断增加
      • 改革和支持神经胶质瘤治疗的倡议
    • 抑制因素
      • 联合治疗费用高
    • 机会
      • 精准医疗技术的进步
      • 联合研究和开发旨在发现神经胶质瘤的新治疗方法
    • 任务
      • 目前的治疗方法效果有限且副作用大
  • 市场区隔分析
    • 治疗类型：由于放射线治疗越来越受到多种恶性的青睐。
    • 最终用户：研究机构积极致力于推进神经胶质瘤治疗并开发新的治疗策略。
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章按神经胶质瘤类型分類的神经胶质瘤治疗市场

  • 高恶性恶性胶质瘤
  • 恶性胶质瘤

第七章依治疗类型分類的神经胶质瘤治疗市场

  • 化疗
  • 免疫疗法
  • 放射治疗
  • 标靶治疗

第八章神经胶质瘤治疗市场：依最终用户分类

  • 医院
  • 调查机构
  • 专科诊所

第九章神经胶质瘤治疗市场：按分销管道

  • 医院药房
  • 当地药房
  • 网路药房

第10章美洲胶质瘤治疗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太地区神经胶质瘤治疗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章欧洲、中东和非洲的胶质瘤治疗市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • TLX101-CDx PET 显影剂在神经胶质瘤表征和治疗的进展
    • MimiVax, Inc. 获得策略性投资以推进 SurVaxM 在造口治疗方面的发展
    • Rigel Pharmaceuticals, Inc. 和 CONNECT 合作透过创新临床试验推进儿科高级别神经胶质瘤治疗
    • Thermo Fisher 和 UCSF 合作生产用于肿瘤和罕见疾病的先进细胞疗法
  • 战略分析和建议

公司名单

  • Amgen Inc.
  • Azurity Pharmaceuticals, Inc.
  • Bristol-Myers Squibb Company
  • Emcure Pharmaceuticals Ltd.
  • F. Hoffmann-La Roche Ltd
  • Intas Pharmaceuticals Ltd.
  • Karyopharm Therapeutics Inc.
  • Mayo Clinic
  • Merck & Co Inc.
  • MimiVax, Inc.
  • Pfizer Inc.
  • Rigel Pharmaceuticals Inc.
  • Sumitomo Dainippon Pharma Oncology Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceuticals Industries Ltd.
  • Thermo Fisher Scientific Inc.
Product Code: MRR-CD5A9334CE36

The Glioma Treatment Market was valued at USD 4.95 billion in 2023, expected to reach USD 5.29 billion in 2024, and is projected to grow at a CAGR of 7.43%, to USD 8.18 billion by 2030.

Glioma treatment refers to the comprehensive methodologies and therapies aimed at managing gliomas, a type of brain tumor arising from glial cells. The necessity for glioma treatment is underscored by the aggressive nature of these tumors, necessitating innovative solutions that can range from surgical interventions and radiation therapy to cutting-edge immunotherapies and targeted drugs. The scope of application extends to hospitals, specialized cancer treatment centers, and personalized home care settings, catering to diverse patient needs across different stages of the disease. Key end-use segments include healthcare providers and pharmaceutical companies focusing on the development and delivery of efficacious therapies. Market growth is influenced by several factors, including increasing prevalence of brain tumors, advances in medical technology, and government initiatives promoting cancer research. Moreover, ongoing clinical trials and heightened awareness about early diagnosis present significant opportunities for innovation. Companies can capitalize on these potentials by investing in research for biomarker discovery and development of non-invasive therapeutic options. However, market expansion faces challenges such as high treatment costs, regulatory complexities, and limited availability of advanced therapies in emerging regions. The competitive landscape is shaped by rapid technological advancements, making it imperative for businesses to prioritize R&D and forge strategic partnerships. Areas with the most promise for innovation include personalized medicine approaches, integration of artificial intelligence in diagnostic tools, and expansion of telemedicine for patient management. The glioma treatment market is dynamic, characterized by fierce competition and the constant evolution of therapeutic protocols. Firms looking to thrive should focus on expanding their product pipelines, enhancing collaboration with research bodies, and tapping into underserved markets to sustain growth and achieve significant market differentiation.

KEY MARKET STATISTICS
Base Year [2023] USD 4.95 billion
Estimated Year [2024] USD 5.29 billion
Forecast Year [2030] USD 8.18 billion
CAGR (%) 7.43%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Glioma Treatment Market

The Glioma Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of gliomas globally
    • Reforms and support initiatives for glioma treatment
  • Market Restraints
    • High cost of combination treatment
  • Market Opportunities
    • Advancements in precision medicine technologies
    • Collaborative R&D efforts aimed at discovering novel therapies for glioma
  • Market Challenges
    • Limited efficacy and side effects of current treatments

Porter's Five Forces: A Strategic Tool for Navigating the Glioma Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Glioma Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Glioma Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Glioma Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Glioma Treatment Market

A detailed market share analysis in the Glioma Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Glioma Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Glioma Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Glioma Treatment Market

A strategic analysis of the Glioma Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Glioma Treatment Market, highlighting leading vendors and their innovative profiles. These include Amgen Inc., Azurity Pharmaceuticals, Inc., Bristol-Myers Squibb Company, Emcure Pharmaceuticals Ltd., F. Hoffmann-La Roche Ltd, Intas Pharmaceuticals Ltd., Karyopharm Therapeutics Inc., Mayo Clinic, Merck & Co Inc., MimiVax, Inc., Pfizer Inc., Rigel Pharmaceuticals Inc., Sumitomo Dainippon Pharma Oncology Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceuticals Industries Ltd., and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Glioma Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type of Glioma, market is studied across High-grade Gliomas and Low-grade Gliomas.
  • Based on Treatment Type, market is studied across Chemotherapy, Immunotherapy, Radiation Therapy, and Targeted Therapy.
  • Based on End-user, market is studied across Hospitals, Research Institutes, and Specialty Clinics.
  • Based on Distribution Channel, market is studied across Hospital Pharmacies, Local Pharmacies, and Online Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of gliomas globally
      • 5.1.1.2. Reforms and support initiatives for glioma treatment
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of combination treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements in precision medicine technologies
      • 5.1.3.2. Collaborative R&D efforts aimed at discovering novel therapies for glioma
    • 5.1.4. Challenges
      • 5.1.4.1. Limited efficacy and side effects of current treatments
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Treatment Type: Growing preference for radiation therapy for widespread and aggressive tumors due to its efficacy
    • 5.2.2. End-user: Research institutes actively working on advancing glioma treatment and developing new therapeutic strategies
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Glioma Treatment Market, by Type of Glioma

  • 6.1. Introduction
  • 6.2. High-grade Gliomas
  • 6.3. Low-grade Gliomas

7. Glioma Treatment Market, by Treatment Type

  • 7.1. Introduction
  • 7.2. Chemotherapy
  • 7.3. Immunotherapy
  • 7.4. Radiation Therapy
  • 7.5. Targeted Therapy

8. Glioma Treatment Market, by End-user

  • 8.1. Introduction
  • 8.2. Hospitals
  • 8.3. Research Institutes
  • 8.4. Specialty Clinics

9. Glioma Treatment Market, by Distribution Channel

  • 9.1. Introduction
  • 9.2. Hospital Pharmacies
  • 9.3. Local Pharmacies
  • 9.4. Online Pharmacies

10. Americas Glioma Treatment Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Glioma Treatment Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Glioma Treatment Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Advancements in Glioma Characterization and Treatment Through TLX101-CDx PET Imaging Agent
    • 13.3.2. MimiVax, Inc. Secures Strategic Investments to Advance SurVaxM in Glioblastoma Treatment
    • 13.3.3. Rigel Pharmaceuticals, Inc. and CONNECT Join Forces to Advance Pediatric High-Grade Glioma Treatment Through Innovative Clinical Trial
    • 13.3.4. Thermo Fisher and UCSF Collaborate on Advanced Cell Therapies Manufacturing for Oncological and Rare Diseases
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Amgen Inc.
  • 2. Azurity Pharmaceuticals, Inc.
  • 3. Bristol-Myers Squibb Company
  • 4. Emcure Pharmaceuticals Ltd.
  • 5. F. Hoffmann-La Roche Ltd
  • 6. Intas Pharmaceuticals Ltd.
  • 7. Karyopharm Therapeutics Inc.
  • 8. Mayo Clinic
  • 9. Merck & Co Inc.
  • 10. MimiVax, Inc.
  • 11. Pfizer Inc.
  • 12. Rigel Pharmaceuticals Inc.
  • 13. Sumitomo Dainippon Pharma Oncology Inc.
  • 14. Sun Pharmaceutical Industries Ltd.
  • 15. Teva Pharmaceuticals Industries Ltd.
  • 16. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLIOMA TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. GLIOMA TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL GLIOMA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS GLIOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS GLIOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES GLIOMA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES GLIOMA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC GLIOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC GLIOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA GLIOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA GLIOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. GLIOMA TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. GLIOMA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. GLIOMA TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL GLIOMA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. GLIOMA TREATMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY HIGH-GRADE GLIOMAS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY LOW-GRADE GLIOMAS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY LOCAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS GLIOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES GLIOMA TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC GLIOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA GLIOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 191. GLIOMA TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 192. GLIOMA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023